Repros Announces Acceptance for Filing of NDA

THE WOODLANDS, Texas, April 1, 2015 -- Repros Therapeutics Inc.(R) (RPRX) today announced that the New Drug Application (NDA) for its enclomiphene citrate product candidate, formerly known as Androxal(R), has been accepted by the U.S. Food and Drug Administration (FDA), indicating that the application is sufficiently complete to permit a substantive review. This investigational product, which is the Company's lead product candidate, is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound. The Company is developing this product candidate for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. The Company's product candidate is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism.

NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease at the 67th Annual Meeting of the American Academy of Neurology

REHOVOT, Israel, April 1, 2015 -- NeuroDerm Ltd. (NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that updated results from the Phase II Study assessing the safety, tolerability and pharmacokinetics (PK) of ND0612L will be presented at the American Academy of Neurology (AAN) 67^th Annual Meeting taking place April 18 to 25, 2015 in Washington, DC.

ND0612L is the low-dose product candidate of NeuroDerm's proprietary liquid Levodopa/Carbidopa (LD/CD) formulation that provides continuous, subcutaneously-delivered treatment for patients with moderate to severe Parkinson's disease.

Trillium Therapeutics Announces Pricing of Public Offering of Securities

TORONTO, April 1, 2015 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TRIL) (TR.TO) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced an underwritten public offering of 1,522,395 common shares and 1,077,605 non-voting convertible preferred shares at a price of US$19.50 per share for aggregate gross proceeds of US$50.7 million before deducting underwriting discounts and commissions and other offering expenses.

Trillium has also granted the underwriters a 30-day option to purchase up to an additional 228,359 common shares, which, if exercised, would result in additional gross proceeds of approximately US$4.45 million. The offering is expected to close on or about April 7, 2015, subject to the satisfaction of customary closing conditions.

Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents

SEATTLE and SAN FRANCISCO, March 31, 2015 -- Immune Design (IMDZ), a clinical-stage immunotherapy company focused on cancer, reported today that analyses of data from three ongoing Phase 1 studies support continued development of its two primary product candidates, CMB305 and G100.

CMB305 and G100 represent Immune Design's two distinct approaches to fighting cancer via the in vivo induction and/or expansion of anti-tumor CD8 T cells.